Vascular Endothelial Growth Factor B (VEGFB), encoded by the VEGFB gene located on chromosome 11q13.1, is a secreted signaling protein belonging to the VEGF family of growth factors. VEGFB exists in two main isoforms generated through alternative splicing: VEGFB167 (the predominant form in most tissues) and VEGFB186. This protein is approximately 20 kDa in molecular weight and functions as a dimeric ligand that binds to receptor tyrosine kinases on the cell surface. Unlike some other VEGF family members, VEGFB exhibits more restricted tissue distribution, with particularly high expression in the heart, skeletal muscle, and nervous system. Its discovery revealed a distinct signaling pathway separate from the canonical VEGFA-driven angiogenic cascade, establishing VEGFB as a specialized regulator of vascular homeostasis and metabolic adaptation.
Function and Biology
...
VEGFB Protein
Overview
Vascular Endothelial Growth Factor B (VEGFB), encoded by the VEGFB gene located on chromosome 11q13.1, is a secreted signaling protein belonging to the VEGF family of growth factors. VEGFB exists in two main isoforms generated through alternative splicing: VEGFB167 (the predominant form in most tissues) and VEGFB186. This protein is approximately 20 kDa in molecular weight and functions as a dimeric ligand that binds to receptor tyrosine kinases on the cell surface. Unlike some other VEGF family members, VEGFB exhibits more restricted tissue distribution, with particularly high expression in the heart, skeletal muscle, and nervous system. Its discovery revealed a distinct signaling pathway separate from the canonical VEGFA-driven angiogenic cascade, establishing VEGFB as a specialized regulator of vascular homeostasis and metabolic adaptation.
Function and Biology
VEGFB primarily signals through two receptor tyrosine kinases: VEGFR1 (Flt-1) and Neuropilin-1 (NRP1), with VEGFR1 being the primary functional receptor. Binding to these receptors triggers phosphorylation of intracellular tyrosine residues, activating downstream signaling cascades including the PI3K/AKT pathway, MAPK/ERK pathway, and PLCγ pathway. These cascades regulate endothelial cell survival, metabolic adaptation, and vascular stability rather than promoting new blood vessel formation. VEGFB is unique among VEGF ligands for its strong interaction with heparan sulfate proteoglycans (HSPGs) through a heparin-binding domain, allowing for tissue-specific retention and localized signaling. In metabolic tissues, VEGFB regulates fatty acid uptake and mitochondrial oxidative metabolism through endothelial cells, acting as a metabolic rheostat that coordinates vascular function with tissue energy demands.
Role in Neurodegeneration
Emerging evidence implicates VEGFB dysfunction in multiple neurodegenerative conditions. The protein supports the neurovascular unit—the functional complex comprising endothelial cells, pericytes, astrocytes, and neurons—which is increasingly recognized as critical for neuronal survival in age-related neurodegeneration. VEGFB maintains blood-brain barrier (BBB) integrity by promoting endothelial cell survival and tight junction stability, effects mediated through reduced vascular permeability and enhanced pericyte recruitment. In Alzheimer's disease, impaired cerebral VEGFB signaling correlates with neurovascular dysfunction, reduced cerebral blood flow, and accumulation of amyloid-beta. Similarly, Parkinson's disease models demonstrate that VEGFB deficiency exacerbates dopaminergic neuronal loss through compromised vascular support and metabolic adaptation. In ALS, motor neuron vulnerability is partly attributed to reduced VEGFB expression in affected motor cortex and spinal cord regions, contributing to neurovascular breakdown and motor neuron degeneration.
Molecular Mechanisms
In the neurodegeneration context, VEGFB dysfunction operates through several interconnected mechanisms. Reduced VEGFB signaling compromises mitochondrial oxidative metabolism in cerebral endothelial cells, diminishing their capacity to support metabolically demanding neurons. The protein's role in maintaining endothelial cell survival through PI3K/AKT signaling becomes particularly critical with aging, as VEGFB expression declines naturally in aged tissues. Loss of VEGFB-mediated BBB maintenance increases pathological neuroinflammation by allowing peripheral immune cell infiltration. Additionally, VEGFB regulates ceramide metabolism and fatty acid oxidation in vascular cells—pathways increasingly implicated in neurodegeneration. The protein also modulates angiogenesis-independent endothelial functions including nitric oxide production and vascular tone regulation, both essential for maintaining cerebral perfusion pressures adequate for neuronal function.
Clinical and Research Significance
VEGFB represents a promising therapeutic target for neurodegenerative diseases, distinct from strategies targeting VEGFA. Pre-clinical studies demonstrate that VEGFB augmentation protects against neurodegeneration in models of Alzheimer's disease, Parkinson's disease, and stroke. Unlike VEGFA-driven angiogenesis approaches that risk complications including vascular leakage and edema, VEGFB therapy focuses on metabolic adaptation and vascular stabilization. Clinical interest centers on recombinant VEGFB administration and gene therapy approaches to restore impaired VEGFB signaling in aging brains.